EMERYVILLE, Calif., Jan. 6, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that in tests conducted at a third-party laboratory, NovaBay's lead Aganocide, NVC-422 has shown in vitro activity against the "superbug" New Delhi Metallo-beta-lactamase-1 (NDM-1)-encoded Klebsiella pneumoniae at a very low concentration of 2 mg/mL. In comparison, Imipenem, which is a mainstay antibiotic for the treatment of antibiotic-resistant bacterial infections, is not effective against NDM-1-encoded strains.
